Brief: Oncosil Medical Reports FY Loss Attributable A$15.1 Million
29/08/2025 03:52
Aug 29 (Reuters) - Oncosil Medical Ltd OSL.AX: FY LOSS ATTRIBUTABLE A$15.1 MILLION FY REVENUES FROM ORDINARY ACTIVITIES A$1.2 MILLION Further company coverage: OSL.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncosil Medical
See all newsAustralia's OncoSil Medical gains most in over 2 months on reaching 100-th patient milestone
Brief: Oncosil Medical Says FDA Grants Hde Approval For Oncosil Device For Distal Cholangiocarcinoma
Brief: Oncosil Medical Posts FY26 Unit Sales Up 53%, Revenue Up 44% Versus FY25
Brief: Oncosil Medical Receives Saudi FDA Approval
Brief: Oncosil Medical Files For FDA Approval